von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.

Article  PubMed  Google Scholar 

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–48.

Article  CAS  PubMed  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sidaway P. Sacituzumab govitecan is safe and effective. Nat Rev Clin Oncol. 2021;18(7):400.

PubMed  Google Scholar 

Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, et al. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study. Int J Urol. 2024;31(4):342–7.

Article  CAS  PubMed  Google Scholar 

Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, et al. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan. J Cancer Res Clin Oncol. 2024;150(4):182.

Article  PubMed  PubMed Central  Google Scholar 

Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, et al. Durable response to enfortumab vedotin compared to re-challenging chemotherapy in metastatic urothelial carcinoma after checkpoint inhibitors. Target Oncol. 2024;19(3):401-10.

Article  PubMed  Google Scholar 

Komura K, Hashimoto T, Tsujino T, Muraoka R, Tsutsumi T, Satake N, et al. The CANLPH score, an integrative model of systemic inflammation and nutrition status (SINS), predicts clinical outcomes after surgery in renal cell carcinoma: data from a multicenter cohort in Japan. Ann Surg Oncol. 2019;26(9):2994–3004.

Article  PubMed  Google Scholar 

Uchimoto T, Komura K, Fujiwara Y, Saito K, Tanda N, Matsunaga T, et al. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Med Oncol. 2019;37(1):9.

Article  PubMed  Google Scholar 

Tsujino T, Komura K, Matsunaga T, Yoshikawa Y, Takai T, Uchimoto T, et al. Preoperative measurement of the Modified Glasgow Prognostic Score predicts patient survival in non-metastatic renal cell carcinoma prior to nephrectomy. Ann Surg Oncol. 2017;24(9):2787–93.

Article  PubMed  Google Scholar 

Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, et al. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma: a data from multi-institutional study in Japan. Urol Oncol. 2019;37(11):812.e1-8.

Article  CAS  PubMed  Google Scholar 

Guo Y, Cai K, Mao S, Zhang J, Wang L, Zhang Z, et al. Preoperative C-reactive protein/albumin ratio is a significant predictor of survival in bladder cancer patients after radical cystectomy: a retrospective study. Cancer Manag Res. 2018;10:4789–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kunizaki M, Tominaga T, Wakata K, Miyazaki T, Matsumoto K, Sumida Y, et al. Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma. Mol Clin Oncol. 2018;8(2):370–4.

CAS  PubMed  Google Scholar 

Kuboki A, Kanaya H, Nakayama T, Konno W, Goto K, Nakajima I, et al. Prognostic value of C-reactive protein/albumin ratio for patients with hypopharyngeal and laryngeal cancer undergoing invasive surgery involving laryngectomy. Head Neck. 2019;41(5):1342–50.

Article  PubMed  Google Scholar 

Koh YW, Lee HW. Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Medicine (Baltimore). 2017;96(19): e6848.

Article  CAS  PubMed  Google Scholar 

Wu M, Zhou Y, Chen Q, Yu Z, Gu H, Lin P, et al. Prognostic role of pretreatment C-reactive protein to albumin ratio in urological cancers: a systematic review and meta-analysis. Front Oncol. 2022;12: 879803.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Q, He Q, He W, Wang C, Liu G, Wang K, et al. Clinical value of folate receptor-positive circulating tumor cells in patients with esophageal squamous cell carcinomas: a retrospective study. BMC Cancer. 2023;23(1):1171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gandevia B, Tovell A. Declaration of Helsinki. Med J Aust. 1964;2:320–1.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.

Article  PubMed  PubMed Central  Google Scholar 

Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.

Article  CAS  PubMed  Google Scholar 

Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641–61.

Article  CAS  PubMed  Google Scholar 

Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flechon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu J, Wang D, Liu C, Huang R, Gao F, Feng X, et al. Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: a multicenter study. Front Immunol. 2023;14:1165510.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Z, Yin XN, Wang J, Chen X, Cai ZL, Zhang B. Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: a propensity matched retrospective cohort study. World J Gastroenterol. 2022;28(27):3476–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zakosek M, Bulatovic D, Pavlovic V, Filipovic A, Igic A, Galun D, et al. Prognostic Nutritional Index (PNI) and neutrophil to lymphocyte ratio (NLR) as predictors of short-term survival in patients with advanced malignant biliary obstruction treated with percutaneous transhepatic biliary drainage. J Clin Med. 2022;11(23):7055.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, et al. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. Int J Clin Oncol. 2022;27(1):59–71.

Article  CAS  PubMed  Google Scholar 

Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, et al. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014;113(5b):E137–43.

Article  CAS  PubMed  Google Scholar 

Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014;66(6):1157–64.

Article  PubMed  Google Scholar 

Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5.

Article  PubMed  Google Scholar 

Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, et al. Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma. Urol Oncol. 2022;40(7):344 (e11–7).

Article  Google Scholar 

Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, et al. Risk classification for overall survival by the neutrophil-lymphocyte ratio and the number of metastatic sites in patients treated with pembrolizumab: a multicenter collaborative study in Japan. Cancers (Basel). 2021;13(14):3554.

Article  CAS  PubMed  PubMed Central